Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience

Mutations in the tumor suppressor gene TP53 are detected in 5-10% of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes. TP53 mutations have been associated with complex karyotypes, therapy-related malignancies, lower response rates to cytotoxic chemotherapy, and an overall adv...

Full description

Saved in:
Bibliographic Details
Published inLeukemia & lymphoma Vol. 61; no. 9; pp. 2180 - 2190
Main Authors Bewersdorf, Jan Philipp, Shallis, Rory M., Gowda, Lohith, Wei, Wei, Hager, Karl, Isufi, Iris, Kim, Tae Kon, Pillai, Manoj M., Seropian, Stuart, Podoltsev, Nikolai A., Gore, Steven D., Siddon, Alexa J., Zeidan, Amer M.
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 28.07.2020
Subjects
Acute myeloid leukemia
AML
Humans
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
MDS
Mutation
myelodysplastic syndrome
Myelodysplastic Syndromes - genetics
Myelodysplastic Syndromes - therapy
Retrospective Studies
stem cell transplant
TP53
Tumor Suppressor Protein p53 - genetics
AML
stem cell transplant
myelodysplastic syndrome
Acute myeloid leukemia
MDS
TP53
Online AccessGet full text

Cover

More Information
Summary:Mutations in the tumor suppressor gene TP53 are detected in 5-10% of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes. TP53 mutations have been associated with complex karyotypes, therapy-related malignancies, lower response rates to cytotoxic chemotherapy, and an overall adverse prognosis. In this single-center retrospective study, we analyzed the clinicopathologic characteristics and outcomes of 83 patients with TP53-mutated myeloid malignancies treated at Yale Cancer Center between 9/2015 and 5/2019. Complex karyotypes (n = 75; 90%) and therapy-related malignancies (n = 32; 39%) were common. Median overall survival (OS) was 7.6 months. Intensive chemotherapy did not improve OS compared to lower-intensity treatment for AML patients. Patients who underwent allogeneic hematopoietic stem cell transplant (alloHSCT) had a significantly longer median OS, despite relatively limited follow-up. In conclusion, our data confirm the limited efficacy of intensive chemotherapy approaches for TP53-mutated patients with myeloid neoplasms and suggest that a minority of patients achieve long-term survival with alloHSCT.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1042-8194
1029-2403
1029-2403
DOI:10.1080/10428194.2020.1759051